Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$7.45
-2.1%
$8.23
$6.23
▼
$11.22
$1.92B0.554.93 million shs4.03 million shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.11
-13.3%
$1.93
$1.10
▼
$4.23
$239.45M3.564.19 million shs5.23 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%-1.04%-2.31%-23.44%+7.49%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%-1.54%-9.22%-55.71%-44.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$7.45
-2.1%
$8.23
$6.23
▼
$11.22
$1.92B0.554.93 million shs4.03 million shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.11
-13.3%
$1.93
$1.10
▼
$4.23
$239.45M3.564.19 million shs5.23 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%-1.04%-2.31%-23.44%+7.49%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
0.00%-1.54%-9.22%-55.71%-44.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.56
Moderate Buy$20.38173.49% Upside
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
2.90
Moderate Buy$14.331,191.29% Upside

Current Analyst Ratings Breakdown

Latest BCRX and CABA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Lower Price TargetBuy$8.00
11/5/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Lower Price TargetOutperform$18.00 ➝ $17.00
10/15/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Reiterated RatingSell (D-)
9/30/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Boost Price TargetNeutral$12.00 ➝ $13.00
9/23/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
UpgradeStrong-Buy
9/22/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
DowngradeHold (C) ➝ Sell (D-)
9/10/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
DowngradeOutperform ➝ Sector Perform$13.00 ➝ $11.00
9/8/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Reiterated RatingBuy$16.00
9/1/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Reiterated RatingBuy$16.00
8/27/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Reiterated RatingHold (C)
8/24/2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
UpgradeStrong-Buy
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$961.51M1.99$1.21 per share6.15($0.57) per share-13.07
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$1.16 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.42N/A10.64N/A-37.40%-92.91%66.56%N/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$167.86M-$1.41N/AN/AN/AN/A-106.78%-83.62%N/A

Latest BCRX and CABA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.3174-$0.28+$0.0374-$0.28$1.67 millionN/A
11/4/2026Q3 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.0919$0.14+$0.0481$0.2660$165.67 million$180.29 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.71
2.64
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
6.55
6.55

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
6.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
435257.30 million247.52 millionOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
158215.72 million201.83 millionOptionable

Recent News About These Companies

Cabaletta Bio: Revisiting A Wrong Call
HC Wainwright Expects Higher Earnings for Cabaletta Bio
Cabaletta Bio (NASDAQ:CABA) Stock Price Target Cut by Citigroup
HC Wainwright Lifts Earnings Estimates for Cabaletta Bio
FY2030 EPS Estimate for Cabaletta Bio Decreased by Analyst
Cabaletta Bio (NASDAQ:CABA) Raised to Sell at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$7.45 -0.16 (-2.10%)
Closing price 04:00 PM Eastern
Extended Trading
$7.46 +0.01 (+0.20%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.11 -0.17 (-13.28%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 +0.01 (+1.35%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.